• Oklahoma Heart Institute contracts with Imricor to join VISABL-AFL clinical trial
• OHI is the fourth U.S. site to participate in the trial, supporting FDA approval process
• Cardiology-owned MRI infrastructure at OHI expected to accelerate adoption and implementation

Imricor Medical Systems, Inc. (ASX: IMR) has announced that Oklahoma Heart Institute (OHI) has contracted with Imricor to join the company's VISABL-AFL clinical trial, supporting the U.S. FDA approval process for Imricor's ablation products. OHI is now the fourth U.S. site to join the trial, alongside the University of Virginia (UVA) Health, Virginia Commonwealth University (VCU) Health and Johns Hopkins University (JHU). Oklahoma Heart Institute is a specialty hospital with established cardiology-owned cardiac MRI (CMR) facilities. Cardiology ownership of MRI infrastructure can materially reduce capital and organizational barriers to adoption and accelerate the implementation of interventional cardiac MRI (iCMR) procedures. Imricor has identified multiple U.S. hospitals with existing cardiology-owned MRI infrastructure, which management believes represents a favorable pathway to faster market adoption and lower hospital capital expenditure. The addition of OHI as a fourth U.S. enrolling site is expected to accelerate patient recruitment for VISABL-AFL, supporting a more efficient FDA approval process. Increased U.S. enrolment capacity also allows European trial sites to complete participation sooner and return to revenue-generating clinical activity. Procedures at OHI are expected to commence in March, with Dr. Edward T. Martin, the Director of Cardiovascular Magnetic Resonance Imaging at OHI, serving as the Principal Investigator for the VISABL-AFL trial at the site.